ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02631044
Recruitment Status : Recruiting
First Posted : December 15, 2015
Last Update Posted : October 12, 2018
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
Juno Therapeutics, Inc.

December 11, 2015
December 15, 2015
October 12, 2018
December 2015
December 2020   (Final data collection date for primary outcome measure)
  • Treatment-related adverse events (AEs) as assessed by CTCAE v4.03 [ Time Frame: Up to 730 days after the final JCAR017 infusion ]
    Physiological parameter
  • Dose-limiting toxicities of JCAR017 [ Time Frame: 28 days after first (single-dose schedule) or second (2-dose schedule) JCAR017 infusion ]
    Physiological parameter
  • Objective response rate (ORR) [ Time Frame: 24 months ]
    Lugano criteria
  • Treatment-related adverse events (AEs) as assessed by CTCAE v4.03 [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
  • Dose-limiting toxicities of JCAR017 [ Time Frame: 28 days after first (single-dose schedule) or second (2-dose schedule) JCAR017 infusion ]
  • Maximum concentration of JCAR017 (Cmax) in the peripheral blood and bone marrow [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
  • Time to maximum concentration of JCAR017 (Tmax) in the peripheral blood and bone marrow [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
  • Area-under-the-concentration-vs-time-curve (AUC) in the peripheral blood and bone marrow [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
Complete list of historical versions of study NCT02631044 on ClinicalTrials.gov Archive Site
  • Complete response (CR) rate [ Time Frame: 24 months ]
    Lugano criteria
  • Duration of response [ Time Frame: 24 months ]
    Lugano criteria
  • Progression-free survival (PFS) [ Time Frame: 24 months ]
    Lugano criteria
  • Overall survival [ Time Frame: Up to 15 years ]
    Physiological parameter
  • Health-related quality of life [ Time Frame: 24 months ]
    Questionnaire
  • Maximum concentration of JCAR017 (Cmax) in the peripheral blood [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
    qPCR
  • Time to maximum concentration of JCAR017 (Tmax) in the peripheral blood [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
    qPCR
  • Area-under-the-concentration-vs-time-curve (AUC) in the peripheral blood [ Time Frame: Up to 365 days after the final JCAR017 infusion ]
    qPCR
  • Rate of complete response (CR), rate of partial response (PR), and objective response rate (ORR) [ Time Frame: 12 months ]
  • Duration of response (DOR) [ Time Frame: 12 months ]
  • Progression-free survival (PFS) [ Time Frame: 12 months ]
  • Overall survival [ Time Frame: Up to 15 years ]
Not Provided
Not Provided
 
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.

This is an open-label, multicenter Phase 1 study to determine the safety, pharmacokinetics (PK), and antitumor activity of JCAR017 in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma Grade 3B, and mantle cell lymphoma (MCL). This study will evaluate and refine the dose and schedule of JCAR017 to optimize safety and antitumor activity. A dose-confirmation group or groups will further evaluate the safety and efficacy of JCAR017 at the recommended regimen(s).

Upon successful generation of JCAR017 product, participants will receive treatment with one or more cycles of JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one or two doses of JCAR017 administered by intravenous (IV) injection.

The follow-up period for each participant is approximately 24 months after the final JCAR017 infusion. Long-term follow-up for survival, toxicity, and viral vector safety will continue under a separate long-term follow-up protocol per health regulatory authority guidelines, currently up to 15 years after the last JCAR017 infusion.

Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Non-Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Mantle-cell Lymphoma
  • Primary Mediastinal B-cell Lymphoma
  • Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule
    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
  • Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule
    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
  • Experimental: JCAR017 1-dose schedule
    Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
    Intervention: Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule
  • Experimental: JCAR017 2-dose schedule
    Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
    Intervention: Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
274
70
December 2020
December 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age ≥18 years
  2. Relapsed or refractory B-cell NHL, including

    1. DLBCL cohort: DLBCL, not otherwise specified (NOS; includes transformed DLBCL from indolent histology [tDLBCL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (Swerdlow 2016), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 lines of therapy or after auto-HSCT.
    2. MCL cohort: MCL (diagnosis must be confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease after at least 1 prior line of MCL therapy
  3. PET-positive disease by Lugano classification
  4. Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If a subject has never had a complete response, a sample from the most recent biopsy is acceptable.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  6. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function
  7. Adequate vascular access for leukapheresis procedure
  8. Participants who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy.
  9. Participants must agree to use appropriate contraception.

Exclusion Criteria:

  1. Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)
  2. History of other primary malignancy not in remission for at least 2 years (The following are exempt from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)
  3. Treatment with alemtuzumab within 6 months of leukapheresis or fludarabine or cladribine within 3 months of leukapheresis
  4. Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
  5. Uncontrolled systemic fungal, bacterial, viral, or other infection
  6. Presence of graft-vs-host disease (GVHD)
  7. History of cardiovascular disease
  8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
  9. Pregnant or nursing women
  10. Use of the following:

    • Therapeutic doses of corticosteroids (defined as >20 mg/day prednisone or equivalent) within 7 days of leukapheresis or 72 hours prior to JCAR017 administration. Physiologic replacement, topical, and inhaled steroids are permitted.
    • Low dose chemotherapy (e.g., vincristine, rituximab, cyclophosphamide ≤300 mg/m2) given after leukapheresis to maintain disease control must be stopped ≥7 days prior to lymphodepleting chemotherapy.
    • Cytotoxic chemotherapeutic agents that are not considered lymphotoxic (see below) within 1 week of leukapheresis. Oral chemotherapeutic agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to leukapheresis.
    • Lymphotoxic chemotherapeutic agents (e.g., cyclophosphamide, ifosofamide, bendamustine) within 2 weeks of leukapheresis.
    • Experimental agents within 4 weeks of leukapheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis
    • Immunosuppressive therapies within 4 weeks of leukapheresis and JCAR017 administration (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolyate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti IL6, or anti-IL6R)
    • Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration
    • Radiation within 6 weeks of leukapheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to leukapheresis.
    • Allo-HSCT within 90 days of leukapheresis
  11. Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JCAR017 treatment in this protocol for subjects receiving retreatment
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Juno Therapeutics 1-866-599-JUNO (5866) medicalinformation@junotherapeutics.com
United States
 
 
NCT02631044
017001
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Juno Therapeutics, Inc.
Juno Therapeutics, Inc.
Celgene
Study Director: Tina Albertson, MD, PhD Juno Therapeutics, Inc.
Study Director: Jacob Garcia, MD Juno Therapeutics, Inc.
Juno Therapeutics, Inc.
October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP